Navigation Links
PTC Therapeutics Announces Achievement Of Major Milestone In SMA Collaboration
Date:8/8/2013

SOUTH PLAINFIELD, N.J., Aug. 8, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the selection of a development candidate in its spinal muscular atrophy (SMA) collaboration with Roche and the SMA Foundation. The achievement of the milestone triggers a $10 million payment to PTC from Roche.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)  

"We are excited about this important achievement in our SMA program", stated Stuart Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. "This program exemplifies PTC's technology platform and its chemistry and biology expertise applied in an area of great unmet medical need. We are grateful for the exceptional commitment and dedication from our PTC team, as well as from our partners, Roche and the SMA Foundation. The discovery and advancement of a potential new treatment for SMA is a significant milestone for SMA patients and their families."

SMA is caused by a missing or defective SMN1 gene, which results in reduced levels of the survival motor neuron (SMN) protein. It is a genetic neuromuscular disease responsible for the early death of motor neuron cells within the spinal cord leading to muscle atrophy and eventually death in the most severe form of the disease. The oral small molecule compounds in the program target the underlying cause of the disorder by increasing SMN protein levels in the nervous system, muscles, and other tissues. It is estimated that SMA affects approximately 10,000 to 25,000 children and adults in the United States, and that between one in 6,000 and one in 10,000 children are born with this rare disorder.

Luca Santarelli, Head of Neuroscience and Small Molecule Researc
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 Research and Markets has ... Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, ... their offering. The global molecular biology ... and is expected to grow at a CAGR of ... enzymes, kits, & reagents find applications in a large ...
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... August 21, 2014 DNA vaccine pioneer ... in its development of JRC-LAMP-vax, an innovative and safe ... Phase IC studies began this month in Hawaii, moving ... fever. , The Japanese red cedar releases pollen that ... Japan. Mountain Cedar pollen wreaks similar havoc in Colorado, ...
(Date:8/21/2014)... 2014 2014 Deep Research ... a professional and in-depth research report on ... basic Seaweed Fertilizer information, including Seaweed Fertilizer ... as well as industry overview. This research ... market as well as global industry analysis ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... Participant Eyes with Wet AMD ... to Electronic Case Report Forms (eCRFs), ... clinical data solutions on demand company, today expanded its,international ... device company specializing in the early detection of,AMD, has ...
... Dec. 13 Anesiva,Inc. (Nasdaq: ANSV ) ... offering,of 11,111,111 shares of its common stock at ... closing bid price on December 12, 2007, for,approximately ... and commissions (approximately $50 million if the underwriters,over-allotment ...
... existing current 2008 convertible notes, and extended the maturity to 2011 on ... ... Dec. 13 Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: ... Convertible Senior,Notes (the "New Notes") due 2011 and 5,459,574 shares of its ...
Cached Biology Technology:Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial 2Notal Vision chooses TrialStat's ClinicalAnalytics 4.0 for age-related macular degeneration (AMD) device trial 3Anesiva Raises $45 Million in Common Stock Offering 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3
(Date:8/21/2014)... University (ANU) team has successfully replicated one of the ... systems powered by sunlight which could manufacture hydrogen as ... sunlight. It is an exciting prospect to use them ... said Dr Kastoori Hingorani, from the ARC Centre of ... of Biology. , Hydrogen offers potential as a zero-carbon ...
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
(Date:8/20/2014)... research finds life can persist in a cold, dark ... a team that examined waters and sediments from a ... found the extreme environment supports microbial ecosystems. , ... her colleagues has implications for life in other extreme ... The findings are published in the current edition of ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... study by researchers at the Salk Institute for Biological ... its name as "guardian of the genome", not only ... but also controls somatic cell reprogramming. Although scientists ... as skin cells into so-called induced pluripotent stem cells ...
... A chemical found in blueberry leaves has shown a strong ... opening up a new avenue for treating chronic HCV infections, ... to cirrhosis and liver cancer. Among the areas ... of southern Japan, a trend that led Hiroaki Kataoka and ...
... numbers of novel marine microbes could lead to more ... conditions such as epilepsy, diabetes, flu and other viruses, ... such as agrochemicals. Researchers at Heriot-Watt University and ... company Ingenza Ltd are searching for new enzymes for ...
Cached Biology News:Tumor suppressor pulls double shift as reprogramming watchdog 2Tumor suppressor pulls double shift as reprogramming watchdog 3Marine microbes creating green waves in industry 2Marine microbes creating green waves in industry 3
Chicken anti-EEA1...
... Buffers are membrane-filtered isotonic and enzyme-free ... and cell-conditioning agents in either Ca2+- ... or Ca2+- and Mg2+-free phosphate-buffered ... cells from support substrates and each ...
Request Info...
Request Info...
Biology Products: